{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:06:47Z","timestamp":1746331607540},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1038\/ncpcardio0371","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T16:29:57Z","timestamp":1132763397000},"page":"628-638","source":"Crossref","is-referenced-by-count":33,"title":["Chronic heart failure: an overview of conventional treatment versus novel approaches"],"prefix":"10.1038","volume":"2","author":[{"given":"Ulf","family":"Landmesser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpcardio0371_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","volume":"273","author":"R Garg","year":"1995","unstructured":"Garg R and Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273: 1450\u20131456","journal-title":"JAMA"},{"key":"BFncpcardio0371_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772\u2013776","journal-title":"Lancet"},{"key":"BFncpcardio0371_CR3","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN et al. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667\u20131675","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/01.CIR.0000065187.80707.18","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M et al. (2003) \u03b2-blockers in chronic heart failure. Circulation 107: 1570\u20131575","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/01.CIR.101.5.558","volume":"101","author":"MR Bristow","year":"2000","unstructured":"Bristow MR (2000) \u03b2-adrenergic receptor blockade in chronic heart failure. Circulation 101: 558\u2013569","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR6","doi-asserted-by":"crossref","unstructured":"The Beta-Blocker Evaluation of Survival Trial Investigators (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344: 1659\u20131667","DOI":"10.1056\/NEJM200105313442202"},{"key":"BFncpcardio0371_CR7","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","volume":"94","author":"MR Bristow","year":"1996","unstructured":"Bristow MR et al. (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94: 2807\u20132816","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0735-1097(02)01970-8","volume":"40","author":"J Wikstrand","year":"2002","unstructured":"Wikstrand J et al.; Merit-HF Study Group (2002) Dose of metoprolol CR\/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR\/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 40: 491\u2013498","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0371_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0195-668X(02)00743-1","volume":"24","author":"T Simon","year":"2003","unstructured":"Simon T et al. (2003) Bisoprolol dose\u2013response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 24: 552\u2013559","journal-title":"Eur Heart J"},{"key":"BFncpcardio0371_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709\u2013717","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN (2004) et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543\u2013551","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767\u2013771","journal-title":"Lancet"},{"key":"BFncpcardio0371_CR13","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893\u20131906","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR14","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1161\/01.CIR.0000163562.82134.8E","volume":"111","author":"J Katada","year":"2005","unstructured":"Katada J et al. (2005) Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 111: 2157\u20132164","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR15","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.jacc.2003.07.020","volume":"42","author":"AU Khand","year":"2003","unstructured":"Khand AU et al. (2003) Khand AU Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42: 1944\u20131951","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0371_CR16","doi-asserted-by":"crossref","unstructured":"The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525\u2013533","DOI":"10.1056\/NEJM199702203360801"},{"key":"BFncpcardio0371_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jama.289.7.871","volume":"289","author":"SS Rathore","year":"2003","unstructured":"Rathore SS et al. (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871\u2013878","journal-title":"JAMA"},{"key":"BFncpcardio0371_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1056\/NEJMoa021266","volume":"347","author":"SS Rathore","year":"2002","unstructured":"Rathore SS et al. (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347: 1403\u20131411","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR19","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa042934","volume":"351","author":"AL Taylor","year":"2004","unstructured":"Taylor AL et al.; African\u2013American Heart Failure Trial Investigators (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351: 2049\u20132057","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","volume":"5","author":"P Carson","year":"1999","unstructured":"Carson P et al. (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5: 178\u2013187","journal-title":"J Card Fail"},{"key":"BFncpcardio0371_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.289.2.194","volume":"289","author":"MM Redfield","year":"2003","unstructured":"Redfield MM et al. (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194\u2013202","journal-title":"JAMA"},{"key":"BFncpcardio0371_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777\u2013781","journal-title":"Lancet"},{"key":"BFncpcardio0371_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD et al. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215\u2013225","journal-title":"Eur Heart J"},{"key":"BFncpcardio0371_CR24","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/01.CIR.0000055013.92097.40","volume":"107","author":"IL Pina","year":"2003","unstructured":"Pina IL et al. (2003) Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 107: 1210\u20131225","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR25","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"MR Bristow","year":"2004","unstructured":"Bristow MR et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140\u20132150","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","volume":"352","author":"JG Cleland","year":"2005","unstructured":"Cleland JG et al. for the Cardiac Resynchronization\u2014Heart Failure (CARE-HF) Study Investigators (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352: 1539\u20131549","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy GH et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352: 225\u2013237","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR28","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMoa012175","volume":"345","author":"EA Rose","year":"2001","unstructured":"Rose EA et al. for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group (2001) Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345: 1435\u20131443","journal-title":"N Engl J Med"},{"key":"BFncpcardio0371_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1161\/hc3401.095946","volume":"104","author":"J Bauersachs","year":"2001","unstructured":"Bauersachs J et al. (2001) Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104: 982\u2013985","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR30","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/01.CIR.0000143232.67642.7A","volume":"110","author":"U Landmesser","year":"2004","unstructured":"Landmesser U et al. (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, LV function and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110: 1933\u20131939","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.CIR.0000084539.58092.DE","volume":"108","author":"K Node","year":"2003","unstructured":"Node K et al. (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839\u2013843","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR32","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1161\/01.CIR.0000164260.82417.3F","volume":"111","author":"U Landmesser","year":"2005","unstructured":"Landmesser U et al. (2005) Simvastatin versus Ezetimibe: Pleiotropic and lipid lowering effects on endothelial function in humans. Circulation 111: 2356\u20132363","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jacc.2003.07.049","volume":"43","author":"TB Horwich","year":"2004","unstructured":"Horwich TB et al. (2004) Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardio 43: 642\u2013648","journal-title":"J Am Coll Cardio"},{"key":"BFncpcardio0371_CR34","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.jacc.2003.07.016","volume":"42","author":"M Rauchhaus","year":"2003","unstructured":"Rauchhaus M et al. (2003) The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42: 1933\u20131940","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0371_CR35","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","volume":"82","author":"GS Francis","year":"1990","unstructured":"Francis GS et al. (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82: 1724\u20131729","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR36","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M Gheoghiade","year":"2003","unstructured":"Gheoghiade M et al. (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 107: 2690\u20132696","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR37","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M et al. (2004) Effects of tolvaptan vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 291: 1963\u20131971","journal-title":"JAMA"},{"key":"BFncpcardio0371_CR38","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1161\/hc4501.099313","volume":"104","author":"JE Udelson","year":"2001","unstructured":"Udelson JE et al. (2001) Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104: 2417\u20132423","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1067\/mhj.2003.39","volume":"145","author":"SD Russell","year":"2003","unstructured":"Russell SD et al. (2003) Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J 145: 179\u2013186","journal-title":"Am Heart J"},{"key":"BFncpcardio0371_CR40","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cardfail.2005.03.009","volume":"11","author":"M Gheorghiade","year":"2005","unstructured":"Gheorghiade M et al. (2005) Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 11: 260\u2013269","journal-title":"J Card Fail"},{"key":"BFncpcardio0371_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI200524459","volume":"115","author":"JM Hare","year":"2005","unstructured":"Hare JM et al. (2005) NO\/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115: 509\u2013517","journal-title":"J Clin Invest"},{"key":"BFncpcardio0371_CR42","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1161\/01.CIR.0000041431.57222.AF","volume":"106","author":"U Landmesser","year":"2002","unstructured":"Landmesser U et al. (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106: 3073\u20133078","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR43","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1161\/hc4501.098928","volume":"104","author":"TP Cappola","year":"2001","unstructured":"Cappola TP et al. (2001) Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104: 2407\u20132411","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR44","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","volume":"105","author":"W Doehner","year":"2002","unstructured":"Doehner W et al. (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105: 2619\u20132624","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR45","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/01.CIR.0000144303.24894.1C","volume":"110","author":"N Engberding","year":"2004","unstructured":"Engberding N et al. (2004) Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110: 2175\u20132179","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR46","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/01.RES.0000148635.73331.c5","volume":"95","author":"LB Stull","year":"2004","unstructured":"Stull LB et al. (2004) Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 95: 1005\u20131011","journal-title":"Circ Res"},{"key":"BFncpcardio0371_CR47","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1517\/13543784.13.11.1509","volume":"13","author":"RS Freudenberger","year":"2004","unstructured":"Freudenberger RS et al. (2004) Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III \u2013 IV congestive heart failure. Expert Opin Investig Drugs 13: 1509\u20131516","journal-title":"Expert Opin Investig Drugs"},{"key":"BFncpcardio0371_CR48","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1161\/01.CIR.0000052622.51963.FC","volume":"107","author":"JA Ezekowitz","year":"2003","unstructured":"Ezekowitz JA et al. (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107: 223\u2013225","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR49","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.CIR.0000044914.42696.6A","volume":"107","author":"DM Mancini","year":"2003","unstructured":"Mancini DM et al. (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107: 294\u2013299","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR50","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","volume":"37","author":"DS Silverberg","year":"2003","unstructured":"Silverberg DS et al. (2003) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37: 1775\u20131780","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0371_CR51","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1172\/JCI18200","volume":"112","author":"CJ Parsa","year":"2003","unstructured":"Parsa CJ et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999\u20131007","journal-title":"J Clin Invest"},{"key":"BFncpcardio0371_CR52","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1073\/pnas.0630444100","volume":"100","author":"L Calvillo","year":"2003","unstructured":"Calvillo L et al. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802\u20134806","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpcardio0371_CR53","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2003-04-1284","volume":"103","author":"FH Bahlmann","year":"2004","unstructured":"Bahlmann FH et al. (2004) Erythropoietin regulates endothelial progenitor cells. Blood 103: 921\u2013926","journal-title":"Blood"},{"key":"BFncpcardio0371_CR54","first-page":"829","volume-title":"Cardiology","author":"H Drexler","year":"2003","unstructured":"Drexler H and Hassenfuss G (2003) Physiology of the normal and failing heart. In Cardiology, 829\u2013844 edn 2 (Eds Crawford MH et al.) London: WJ Mosby"},{"key":"BFncpcardio0371_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1113\/jphysiol.2002.026732","volume":"546","author":"F del Monte","year":"2003","unstructured":"del Monte F et al. (2003) Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol 546: 49\u201361","journal-title":"J Physiol"},{"key":"BFncpcardio0371_CR56","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm739","volume":"8","author":"M Hoshijima","year":"2002","unstructured":"Hoshijima M et al. (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8: 864\u2013871","journal-title":"Nat Med"},{"key":"BFncpcardio0371_CR57","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1081578","volume":"299","author":"JP Schmitt","year":"2003","unstructured":"Schmitt JP et al. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299: 1410\u20131413","journal-title":"Science"},{"key":"BFncpcardio0371_CR58","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath F et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360: 196\u2013202","journal-title":"Lancet"},{"key":"BFncpcardio0371_CR59","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1172\/JCI17664","volume":"111","author":"D Wencker","year":"2003","unstructured":"Wencker D et al. (2003) A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111: 1497\u20131504","journal-title":"J Clin Invest"},{"key":"BFncpcardio0371_CR60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/01.RES.0000153667.26414.10","volume":"96","author":"FP Limbourg","year":"2005","unstructured":"Limbourg FP et al. (2005) Bone marrow stem cells for myocardial infarction: effector or mediator? Circ Res 96: 6\u20138","journal-title":"Circ Res"},{"key":"BFncpcardio0371_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0140-6736(00)03617-5","volume":"357","author":"P Menasch\u00e9","year":"2001","unstructured":"Menasch\u00e9 P et al. (2001) Myoblast transplantation for heart failure. Lancet 357: 279\u2013280","journal-title":"Lancet"},{"key":"BFncpcardio0371_CR62","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/01.RES.0000155333.69009.63","volume":"96","author":"KC Wollert","year":"2005","unstructured":"Wollert KC et al. (2005) Clinical applications of stem cells for the heart. Circ Res 96: 151\u2013163","journal-title":"Circ Res"},{"issue":"Suppl III","key":"BFncpcardio0371_CR63","first-page":"S238","volume":"110","author":"B Assmus","year":"2004","unstructured":"Assmus B et al. (2004) Transcoronary transplantation of progenitor cells and recovery of left ventricular function in patients with chronic ischemic heart disease: results of a randomized, controlled trial. Circulation 110 (Suppl III): S238","journal-title":"Circulation"},{"issue":"Suppl 1","key":"BFncpcardio0371_CR64","first-page":"SII213","volume":"110","author":"EC Perin","year":"2004","unstructured":"Perin EC et al. (2004) Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 110 (Suppl 1): SII213\u2013SII218","journal-title":"Circulation"},{"key":"BFncpcardio0371_CR65","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1161\/01.RES.0000101932.70443.FE","volume":"93","author":"HN Sabbah","year":"2003","unstructured":"Sabbah HN et al. (2003) Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res 93: 1095\u20131101","journal-title":"Circ Res"},{"key":"BFncpcardio0371_CR66","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cardfail.2003.10.007","volume":"10","author":"DL Mann","year":"2004","unstructured":"Mann DL et al.; Acorn Investigators and Study Coordinators (2004) Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. J Card Fail 10: 185\u2013192","journal-title":"J Card Fail"},{"key":"BFncpcardio0371_CR67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jacc.2004.09.073","volume":"45","author":"AH Wu","year":"2005","unstructured":"Wu AH et al. (2005) Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 45: 381\u2013387","journal-title":"J Am Coll Cardiol"}],"container-title":["Nature Clinical Practice Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpcardio0371","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpcardio0371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpcardio0371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:36:26Z","timestamp":1684438586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpcardio0371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["BFncpcardio0371"],"URL":"https:\/\/doi.org\/10.1038\/ncpcardio0371","relation":{},"ISSN":["1743-4297","1743-4300"],"issn-type":[{"value":"1743-4297","type":"print"},{"value":"1743-4300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}